OneDigital Investment Advisors LLC Acquires 8,867 Shares of Insulet Corporation (NASDAQ:PODD)

OneDigital Investment Advisors LLC raised its position in Insulet Corporation (NASDAQ:PODD - Free Report) by 260.9% in the first quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 12,265 shares of the medical instruments supplier's stock after acquiring an additional 8,867 shares during the quarter. OneDigital Investment Advisors LLC's holdings in Insulet were worth $3,221,000 as of its most recent SEC filing.

Other institutional investors have also modified their holdings of the company. SBI Securities Co. Ltd. acquired a new position in shares of Insulet during the 4th quarter valued at about $36,000. Itau Unibanco Holding S.A. acquired a new stake in Insulet in the 4th quarter valued at $42,000. SRS Capital Advisors Inc. grew its stake in shares of Insulet by 43.1% during the fourth quarter. SRS Capital Advisors Inc. now owns 186 shares of the medical instruments supplier's stock worth $49,000 after purchasing an additional 56 shares during the period. Golden State Wealth Management LLC raised its holdings in Insulet by 553.1% during the first quarter. Golden State Wealth Management LLC now owns 209 shares of the medical instruments supplier's stock worth $55,000 after acquiring an additional 177 shares in the last quarter. Finally, Assetmark Inc. lifted its position in shares of Insulet by 1,447.1% during the 4th quarter. Assetmark Inc. now owns 263 shares of the medical instruments supplier's stock valued at $69,000 after acquiring an additional 246 shares during the period.

Insider Buying and Selling at Insulet

In related news, SVP John W. Kapples sold 5,278 shares of the company's stock in a transaction dated Wednesday, May 14th. The shares were sold at an average price of $318.47, for a total transaction of $1,680,884.66. Following the completion of the sale, the senior vice president owned 23,180 shares of the company's stock, valued at approximately $7,382,134.60. This represents a 18.55% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. 0.39% of the stock is owned by company insiders.

Insulet Stock Up 0.6%

PODD stock traded up $1.67 during midday trading on Wednesday, hitting $298.18. The company's stock had a trading volume of 266,648 shares, compared to its average volume of 719,551. Insulet Corporation has a 12 month low of $173.00 and a 12 month high of $329.33. The company has a current ratio of 4.47, a quick ratio of 3.63 and a debt-to-equity ratio of 1.21. The company has a market cap of $20.99 billion, a PE ratio of 53.63, a P/E/G ratio of 2.68 and a beta of 1.35. The firm's 50-day moving average is $304.80 and its 200-day moving average is $279.49.

Insulet (NASDAQ:PODD - Get Free Report) last announced its earnings results on Thursday, May 8th. The medical instruments supplier reported $1.02 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.81 by $0.21. Insulet had a return on equity of 22.25% and a net margin of 18.29%. The business had revenue of $569.00 million during the quarter, compared to analyst estimates of $543.20 million. During the same quarter in the previous year, the business earned $0.73 earnings per share. The company's revenue for the quarter was up 28.8% compared to the same quarter last year. On average, equities research analysts forecast that Insulet Corporation will post 3.92 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

PODD has been the subject of several analyst reports. The Goldman Sachs Group initiated coverage on Insulet in a research note on Friday, May 30th. They issued a "buy" rating and a $380.00 price objective for the company. Sanford C. Bernstein reissued an "outperform" rating on shares of Insulet in a report on Friday, May 16th. Wolfe Research raised Insulet from a "peer perform" rating to an "outperform" rating and set a $350.00 price objective for the company in a report on Tuesday, May 13th. Wells Fargo & Company set a $322.00 price objective on Insulet in a report on Monday, April 28th. Finally, Oppenheimer increased their price objective on Insulet from $312.00 to $324.00 and gave the company an "outperform" rating in a report on Friday, May 9th. Four research analysts have rated the stock with a hold rating and fifteen have assigned a buy rating to the stock. According to MarketBeat.com, Insulet currently has a consensus rating of "Moderate Buy" and a consensus price target of $321.00.

Insulet Company Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.